{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:15:01Z","timestamp":1785798901978,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01848-x","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:51:07Z","timestamp":1751597467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing Gleason score up\/downgrade in radical prostatectomy"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7325-1965","authenticated-orcid":false,"given":"Zafer Gokhan","family":"Gurbuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Vuruskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubariz","family":"Aydamirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Karkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"1848_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38\u201352.","journal-title":"Eur Urol"},{"key":"1848_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P van den Cornford","year":"2021","unstructured":"van den Cornford P, Van den Briers E, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol"},{"key":"1848_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00345-018-2209-7","volume":"36","author":"AA van der Aa","year":"2018","unstructured":"van der Aa AA, Mannaerts CK, van der Linden H, Gayet M, Schrier BP, Mischi M, et al. Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding. World J Urol. 2018;36:863\u20139.","journal-title":"World J Urol"},{"key":"1848_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0022-5347(01)67248-3","volume":"154","author":"AV D\u2019Amico","year":"1995","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995;154:131\u20138.","journal-title":"J Urol"},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/j.1464-410X.2008.08255.x","volume":"103","author":"R Kv\u00e5le","year":"2009","unstructured":"Kv\u00e5le R, M\u00f8ller B, Wahlqvist R, Foss\u00e5 SD, Berner A, Busch C, et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int. 2009;103:1647\u201354.","journal-title":"BJU Int"},{"key":"1848_CR6","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.juro.2008.07.051","volume":"180","author":"RK Berglund","year":"2008","unstructured":"Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180:1964\u20137.","journal-title":"J Urol"},{"key":"1848_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.21037\/tau.2017.12.28","volume":"7","author":"FJH Drost","year":"2018","unstructured":"Drost FJH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, et al. PRIAS study group. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Transl Androl Urol. 2018;7:98\u2013105.","journal-title":"Transl Androl Urol"},{"issue":"9","key":"1848_CR8","first-page":"4175","volume":"27","author":"L Tagliaferri","year":"2023","unstructured":"Tagliaferri L, Alemanno G, Fionda B, Alitto AR, Frascino V, Cellini F, et al. Multiparametric imaging guided HDR interventional radiotherapy (brachytherapy) boost in localized prostate cancer: a multidisciplinary experience. Eur Rev Med Pharmacol Sci. 2023;27(9):4175\u201384.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1848_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.acuro.2016.04.015","volume":"41","author":"H Xu","year":"2017","unstructured":"Xu H, Bai PD, Hu MB, Mao SH, Zhu WH, Hu JM, et al. Gleason sum upgrading between biopsy and radical prostatectomy in Chinese population. Actas Urol Esp. 2017;41:162\u201371.","journal-title":"Actas Urol Esp"},{"key":"1848_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.urology.2018.06.011","volume":"119","author":"SM Monda","year":"2018","unstructured":"Monda SM, Vetter JM, Andriole GL, Fowler KJ, Shetty AS, Weese JR, et al. Cognitive versus software fusion for MRI-targeted biopsy: experience before and after implementation of fusion. Urol. 2018;119:115\u201320.","journal-title":"Urol"},{"key":"1848_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging\u2013reporting and data system: version 2. Eur Urol. 2016;69:16\u201340.","journal-title":"Eur Urol"},{"key":"1848_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917\u201328.","journal-title":"N Engl J Med"},{"key":"1848_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u201352.","journal-title":"Am J Surg Pathol"},{"key":"1848_CR14","volume-title":"TNM classification of malignant tumours. Eighth edition","author":"J Brierley","year":"2017","unstructured":"Brierley J. TNM classification of malignant tumours. Eighth edition. West Sussex, UK; Hoboken, NJ: Wiley Blackwell\/John Wiley & Sons, Inc: ed. Chichester; 2017."},{"key":"1848_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1464-410X.2009.08419.x","volume":"104","author":"V Ficarra","year":"2009","unstructured":"Ficarra V, Novara G, Fracalanza S, D\u2019Elia C, Secco S, Iafrate M, et al. A prospective, non-randomized trial comparing robot\u2010assisted laparoscopic and retropubic radical prostatectomy in one European institution. BJU Int. 2009;104:534\u201349.","journal-title":"BJU Int"},{"key":"1848_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.29271\/jcpsp.2024.10.1205","volume":"34","author":"N Hamidi","year":"2024","unstructured":"Hamidi N, Uzel T, Demirci A, Basar H. Unlocking precision enhancing prostate cancer detection and reducing unnecessary biopsies with combined prostate-specific antigen density and PI-RADS score. J Coll Physicians Surg Pak. 2024;34:1205\u201310.","journal-title":"J Coll Physicians Surg Pak"},{"key":"1848_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.urology.2007.08.055","volume":"70","author":"DJ Hernandez","year":"2007","unstructured":"Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the d\u2019amico risk classification of prostate cancer. Urology. 2007;70:931\u20135.","journal-title":"Urology"},{"key":"1848_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4103\/aja.aja_52_18","volume":"20","author":"H Xu","year":"2018","unstructured":"Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl. 2018;20:551\u20134.","journal-title":"Asian J Androl"},{"key":"1848_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12916-020-01588-9","volume":"18","author":"MG Parry","year":"2020","unstructured":"Parry MG, Cowling TE, Sujenthiran A, Nossiter J, Berry B, Cathcart P, et al. Risk stratification for prostate cancer management: value of the Cambridge prognostic group classification for assessing treatment allocation. BMC Med. 2020;18:114.","journal-title":"BMC Med"},{"key":"1848_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5732\/cjc.013.10137","volume":"33","author":"JY Wang","year":"2014","unstructured":"Wang JY, Zhu Y, Wang CF, Zhang SL, Dai B, Ye DW. A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients. Chin J Cancer. 2014;33:241\u20138.","journal-title":"Chin J Cancer"},{"key":"1848_CR21","doi-asserted-by":"crossref","unstructured":"Imamoto T, Utsumi T, Takano M, Komaru A, Fukasawa S, Suyama T et al. Development and external validation of a nomogram predicting the probability of significant Gleason sum upgrading among Japanese patients with localized prostate cancer. Prostate Cancer. 2011;754382.","DOI":"10.1155\/2011\/754382"},{"key":"1848_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1464-410X.2006.06262.x","volume":"98","author":"FK Chun","year":"2006","unstructured":"Chun FK, Briganti A, Shariat SF, Graefen M, Montorsi F, Erbersdobler A, et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 2006;98:329\u201334.","journal-title":"BJU Int"},{"key":"1848_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2015.12.089","volume":"91","author":"L Quintana","year":"2016","unstructured":"Quintana L, Ward A, Gerrin SJ, Genega EM, Rosen S, Sanda MG, et al. Gleason misclassification rate is independent of number of biopsy cores in systematic biopsy. Urology. 2016;91:143\u20139.","journal-title":"Urology"},{"key":"1848_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.juro.2015.01.102","volume":"194","author":"S Jain","year":"2015","unstructured":"Jain S, Loblaw A, Vesprini D, Zhang L, Kattan MW, Mamedov A, et al. Gleason upgrading with time in a large prostate cancer active surveillance cohort. J Urol. 2015;194:79\u201384.","journal-title":"J Urol"},{"key":"1848_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.urolonc.2008.09.030","volume":"28","author":"FB Serkin","year":"2010","unstructured":"Serkin FB, Soderdahl DW, Cullen J, Chen Y, Hernandez J. Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7. Urol Oncol. 2010;28:302\u20137.","journal-title":"Urol Oncol"},{"key":"1848_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019\u201324.","journal-title":"Eur Urol"},{"key":"1848_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12957-021-02127-3","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang Y, Ji Z, Yang P, Tian Y. Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and meta-analysis. World J Surg Oncol. 2021;19:18.","journal-title":"World J Surg Oncol"},{"key":"1848_CR28","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1002\/cncr.28303","volume":"119","author":"M Truong","year":"2013","unstructured":"Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013;119:3992\u20134002.","journal-title":"Cancer"},{"key":"1848_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prnil.2016.07.004","volume":"4","author":"SM Evans","year":"2016","unstructured":"Evans SM, Bandarage VP, Kronborg C, Earnest A, Millar J, Clouston D. Gleason group concordance between biopsy and radical prostatectomy specimens: a cohort study from Prostate Cancer Outcome Registry\u2013Victoria. Prostate Int. 2016;4:145\u201351.","journal-title":"Prostate Int"},{"key":"1848_CR30","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00432-015-1991-5","volume":"141","author":"C Arsov","year":"2015","unstructured":"Arsov C, Becker N, Rabenalt R, Hiester A, Quentin M, Dietzel F, et al. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol. 2015;141:2061\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1848_CR31","doi-asserted-by":"publisher","first-page":"e13797","DOI":"10.1111\/ijcp.13797","volume":"75","author":"G Aslan","year":"2021","unstructured":"Aslan G, \u00c7elik S, S\u00f6zen S, Akdo\u011fan B, \u0130zol V, Y\u00fccel Bilen C, et al. Comparison of TRUS and combined MRI-targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology. Int J Clin Pract. 2021;75:e13797.","journal-title":"Int J Clin Pract"},{"key":"1848_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5489\/cuaj.6951","volume":"15","author":"J Ryan","year":"2021","unstructured":"Ryan J, Broe MP, Moran D, Mulvin D, Heffernan E, Swan N, et al. Prostate cancer detection with magnetic resonance imaging (MRI)\/cognitive fusion biopsy: comparing standard and targeted prostate biopsy with final prostatectomy histology. Can Urol Assoc J. 2021;15:483\u20137.","journal-title":"Can Urol Assoc J"},{"key":"1848_CR33","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1590\/s1677-5538.ibju.2017.0552","volume":"44","author":"PP Kayano","year":"2018","unstructured":"Kayano PP, Carneiro A, Castilho TML, Sivaraman A, Claros OR, Baroni RH, et al. Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. Int Braz J Urol. 2018;44:1106\u201313.","journal-title":"Int Braz J Urol"},{"key":"1848_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1464-410X.2009.08778.x","volume":"105","author":"AS Moussa","year":"2010","unstructured":"Moussa AS, Kattan MW, Berglund R, Yu C, Fareed K, Jones JS. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int. 2010;105:352\u20138.","journal-title":"BJU Int"},{"key":"1848_CR35","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/pros.24358","volume":"82","author":"Q Hu","year":"2022","unstructured":"Hu Q, Hong X, Xu L, Jia R. A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on 68 Ga-PSMA PET\/CT. Prostate. 2022;82:1077\u201387.","journal-title":"Prostate"},{"key":"1848_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4274\/jus.220","volume":"2","author":"D Bolat","year":"2015","unstructured":"Bolat D, Eski\u00e7orap\u00e7\u0131 S, Karabulut E, Baltac\u0131 S, Y\u0131ld\u0131r\u0131m A, S\u00f6zen S, et al. Can we predict the surgical margin positivity in patients treated with radical prostatectomy?? A multicenter cohort of Turkish association of Uro-Oncology. J Urol Surg. 2015;2:7\u201312.","journal-title":"J Urol Surg"},{"key":"1848_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.juro.2015.08.002","volume":"195","author":"M Kates","year":"2016","unstructured":"Kates M, Sopko NA, Han M, Partin AW, Epstein JI. Importance of reporting the Gleason score at the positive surgical margin site: analysis of 4,082 consecutive radical prostatectomy cases. J Urol. 2016;195:337\u201342.","journal-title":"J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01848-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:51:09Z","timestamp":1751597469000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01848-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01848-x","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethical Committee at Adana City Training and Research Hospital approved the study on 25 May 2023 with approval No. 127\u20132596. A written informed consent form was signed by each participant before completing the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":".","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}